48. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: Risk factors, treatment options and prognosis

Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the only curative option for patients with peritoneal carcinomatosis of colorectal origin. In spite of meticulous preoperative assessment, CRS and HIPEC appears to be impossible in a subset of patients at the time of surgery. This study aimed to investigate which clinical factors may identify these patients prior to surgery and to...